Reviews Trastuzumab


No reviews yet.

Herceptin Drug Description
HERCEPTIN®
(trastuzumab) Intravenous Infusion Initial

WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, and PULMONARY TOXICITY
Cardiomyopathy
Herceptin can result in sub-clinical and clinical cardiac failure manifesting
as CHF and decreased LVEF. The incidence and severity of left ventricular
cardiac dysfunction was highest in patients who received Herceptin concurrently
with anthracycline-containing chemotherapy regimens. Evaluate left ventricular
function in all patients prior to and during treatment with Herceptin. Discontinue
Herceptin treatment in patients receiving adjuvant therapy and strongly consider
discontinuation of Herceptin treatment in patients with metastatic breast
cancer for clinically significant decrease in left ventricular function. [see
WARNINGS and PRECAUTIONS and DOSAGE
AND ADMINISTRATION]
Infusion Reactions; Pulmonary Toxicity
Herceptin administration can result in serious infusion reactions and pulmonary
toxicity. Fatal infusion reactions have been reported. In most cases, symptoms
occurred during or within 24 hours of administration of Herceptin. Herceptin
infusion should be interrupted for patients experiencing dyspnea or clinically
significant hypotension. Patients should be monitored until signs and symptoms
completely resolve. Discontinue Herceptin for infusion reactions manifesting
as anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory
distress syndrome. [see WARNINGS and PRECAUTIONS]

DRUG DESCRIPTION



What are the possible side effects of trastuzumab (Herceptin)?

Some people receiving a trastuzumab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, nauseated, light-headed, weak, itchy, or short of breath during the injection.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

...
Read All Potential Side Effects for Herceptin »




Herceptin (trastuzumab) is a humanized IgG1 kappa monoclonal antibody that
selectively binds with high affinity to the extracellular domain of the human
epidermal growth factor receptor 2 protein, HER2. Trastuzumab is produced by
recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture
containing the antibiotic gentamicin. Gentamicin is not detectable in the final
product.
Herceptin is a sterile, white to pale yellow, preservative-free lyophilized
powder for intravenous administration. Each multi-use vial of Herceptin contains
440 mg trastuzumab, 400 mg α, α-trehalose dihydrate, 9.9 mg L-histidine
HCl, 6.4 mg L-histidine, and 1.8 mg polysorbate 20, USP. Reconstitution with
20 mL of the appropriate diluent (BWFI or SWFI) yields a solution containing
21 mg/mL trastuzumab, at a pH of approximately 6.Last reviewed on RxList: 7/7/2008




Herceptin Drug Description
HERCEPTIN®
(trastuzumab) Intravenous Infusion Initial

WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, and PULMONARY TOXICITY
Cardiomyopathy
Herceptin can result in sub-clinical and clinical cardiac failure manifesting
as CHF and decreased LVEF. The incidence and severity of left ventricular
cardiac dysfunction was highest in patients who received Herceptin concurrently
with anthracycline-containing chemotherapy regimens. Evaluate left ventricular
function in all patients prior to and during treatment with Herceptin. Discontinue
Herceptin treatment in patients receiving adjuvant therapy and strongly consider
discontinuation of Herceptin treatment in patients with metastatic breast
cancer for clinically significant decrease in left ventricular function. [see
WARNINGS and PRECAUTIONS and DOSAGE
AND ADMINISTRATION]
Infusion Reactions; Pulmonary Toxicity
Herceptin administration can result in serious infusion reactions and pulmonary
toxicity. Fatal infusion reactions have been reported. In most cases, symptoms
occurred during or within 24 hours of administration of Herceptin. Herceptin
infusion should be interrupted for patients experiencing dyspnea or clinically
significant hypotension. Patients should be monitored until signs and symptoms
completely resolve. Discontinue Herceptin for infusion reactions manifesting
as anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory
distress syndrome. [see WARNINGS and PRECAUTIONS]

DRUG DESCRIPTION



What are the possible side effects of trastuzumab (Herceptin)?

Some people receiving a trastuzumab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, nauseated, light-headed, weak, itchy, or short of breath during the injection.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

...
Read All Potential Side Effects for Herceptin »




Herceptin (trastuzumab) is a humanized IgG1 kappa monoclonal antibody that
selectively binds with high affinity to the extracellular domain of the human
epidermal growth factor receptor 2 protein, HER2. Trastuzumab is produced by
recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture
containing the antibiotic gentamicin. Gentamicin is not detectable in the final
product.
Herceptin is a sterile, white to pale yellow, preservative-free lyophilized
powder for intravenous administration. Each multi-use vial of Herceptin contains
440 mg trastuzumab, 400 mg α, α-trehalose dihydrate, 9.9 mg L-histidine
HCl, 6.4 mg L-histidine, and 1.8 mg polysorbate 20, USP. Reconstitution with
20 mL of the appropriate diluent (BWFI or SWFI) yields a solution containing
21 mg/mL trastuzumab, at a pH of approximately 6.Last reviewed on RxList: 7/7/2008




Herceptin Drug Description
HERCEPTIN®
(trastuzumab) Intravenous Infusion Initial

WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, and PULMONARY TOXICITY
Cardiomyopathy
Herceptin can result in sub-clinical and clinical cardiac failure manifesting
as CHF and decreased LVEF. The incidence and severity of left ventricular
cardiac dysfunction was highest in patients who received Herceptin concurrently
with anthracycline-containing chemotherapy regimens. Evaluate left ventricular
function in all patients prior to and during treatment with Herceptin. Discontinue
Herceptin treatment in patients receiving adjuvant therapy and strongly consider
discontinuation of Herceptin treatment in patients with metastatic breast
cancer for clinically significant decrease in left ventricular function. [see
WARNINGS and PRECAUTIONS and DOSAGE
AND ADMINISTRATION]
Infusion Reactions; Pulmonary Toxicity
Herceptin administration can result in serious infusion reactions and pulmonary
toxicity. Fatal infusion reactions have been reported. In most cases, symptoms
occurred during or within 24 hours of administration of Herceptin. Herceptin
infusion should be interrupted for patients experiencing dyspnea or clinically
significant hypotension. Patients should be monitored until signs and symptoms
completely resolve. Discontinue Herceptin for infusion reactions manifesting
as anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory
distress syndrome. [see WARNINGS and PRECAUTIONS]

DRUG DESCRIPTION



What are the possible side effects of trastuzumab (Herceptin)?

Some people receiving a trastuzumab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, nauseated, light-headed, weak, itchy, or short of breath during the injection.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

...
Read All Potential Side Effects for Herceptin »




Herceptin (trastuzumab) is a humanized IgG1 kappa monoclonal antibody that
selectively binds with high affinity to the extracellular domain of the human
epidermal growth factor receptor 2 protein, HER2. Trastuzumab is produced by
recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture
containing the antibiotic gentamicin. Gentamicin is not detectable in the final
product.
Herceptin is a sterile, white to pale yellow, preservative-free lyophilized
powder for intravenous administration. Each multi-use vial of Herceptin contains
440 mg trastuzumab, 400 mg α, α-trehalose dihydrate, 9.9 mg L-histidine
HCl, 6.4 mg L-histidine, and 1.8 mg polysorbate 20, USP. Reconstitution with
20 mL of the appropriate diluent (BWFI or SWFI) yields a solution containing
21 mg/mL trastuzumab, at a pH of approximately 6.Last reviewed on RxList: 7/7/2008




Herceptin Drug Description
HERCEPTIN®
(trastuzumab) Intravenous Infusion Initial

WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, and PULMONARY TOXICITY
Cardiomyopathy
Herceptin can result in sub-clinical and clinical cardiac failure manifesting
as CHF and decreased LVEF. The incidence and severity of left ventricular
cardiac dysfunction was highest in patients who received Herceptin concurrently
with anthracycline-containing chemotherapy regimens. Evaluate left ventricular
function in all patients prior to and during treatment with Herceptin. Discontinue
Herceptin treatment in patients receiving adjuvant therapy and strongly consider
discontinuation of Herceptin treatment in patients with metastatic breast
cancer for clinically significant decrease in left ventricular function. [see
WARNINGS and PRECAUTIONS and DOSAGE
AND ADMINISTRATION]
Infusion Reactions; Pulmonary Toxicity
Herceptin administration can result in serious infusion reactions and pulmonary
toxicity. Fatal infusion reactions have been reported. In most cases, symptoms
occurred during or within 24 hours of administration of Herceptin. Herceptin
infusion should be interrupted for patients experiencing dyspnea or clinically
significant hypotension. Patients should be monitored until signs and symptoms
completely resolve. Discontinue Herceptin for infusion reactions manifesting
as anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory
distress syndrome. [see WARNINGS and PRECAUTIONS]

DRUG DESCRIPTION



What are the possible side effects of trastuzumab (Herceptin)?

Some people receiving a trastuzumab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, nauseated, light-headed, weak, itchy, or short of breath during the injection.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

...
Read All Potential Side Effects for Herceptin »




Herceptin (trastuzumab) is a humanized IgG1 kappa monoclonal antibody that
selectively binds with high affinity to the extracellular domain of the human
epidermal growth factor receptor 2 protein, HER2. Trastuzumab is produced by
recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture
containing the antibiotic gentamicin. Gentamicin is not detectable in the final
product.
Herceptin is a sterile, white to pale yellow, preservative-free lyophilized
powder for intravenous administration. Each multi-use vial of Herceptin contains
440 mg trastuzumab, 400 mg α, α-trehalose dihydrate, 9.9 mg L-histidine
HCl, 6.4 mg L-histidine, and 1.8 mg polysorbate 20, USP. Reconstitution with
20 mL of the appropriate diluent (BWFI or SWFI) yields a solution containing
21 mg/mL trastuzumab, at a pH of approximately 6.Last reviewed on RxList: 7/7/2008




Herceptin Drug Description
HERCEPTIN®
(trastuzumab) Intravenous Infusion Initial

WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, and PULMONARY TOXICITY
Cardiomyopathy
Herceptin can result in sub-clinical and clinical cardiac failure manifesting
as CHF and decreased LVEF. The incidence and severity of left ventricular
cardiac dysfunction was highest in patients who received Herceptin concurrently
with anthracycline-containing chemotherapy regimens. Evaluate left ventricular
function in all patients prior to and during treatment with Herceptin. Discontinue
Herceptin treatment in patients receiving adjuvant therapy and strongly consider
discontinuation of Herceptin treatment in patients with metastatic breast
cancer for clinically significant decrease in left ventricular function. [see
WARNINGS and PRECAUTIONS and DOSAGE
AND ADMINISTRATION]
Infusion Reactions; Pulmonary Toxicity
Herceptin administration can result in serious infusion reactions and pulmonary
toxicity. Fatal infusion reactions have been reported. In most cases, symptoms
occurred during or within 24 hours of administration of Herceptin. Herceptin
infusion should be interrupted for patients experiencing dyspnea or clinically
significant hypotension. Patients should be monitored until signs and symptoms
completely resolve. Discontinue Herceptin for infusion reactions manifesting
as anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory
distress syndrome. [see WARNINGS and PRECAUTIONS]

DRUG DESCRIPTION



What are the possible side effects of trastuzumab (Herceptin)?

Some people receiving a trastuzumab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, nauseated, light-headed, weak, itchy, or short of breath during the injection.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

...
Read All Potential Side Effects for Herceptin »




Herceptin (trastuzumab) is a humanized IgG1 kappa monoclonal antibody that
selectively binds with high affinity to the extracellular domain of the human
epidermal growth factor receptor 2 protein, HER2. Trastuzumab is produced by
recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture
containing the antibiotic gentamicin. Gentamicin is not detectable in the final
product.
Herceptin is a sterile, white to pale yellow, preservative-free lyophilized
powder for intravenous administration. Each multi-use vial of Herceptin contains
440 mg trastuzumab, 400 mg α, α-trehalose dihydrate, 9.9 mg L-histidine
HCl, 6.4 mg L-histidine, and 1.8 mg polysorbate 20, USP. Reconstitution with
20 mL of the appropriate diluent (BWFI or SWFI) yields a solution containing
21 mg/mL trastuzumab, at a pH of approximately 6.Last reviewed on RxList: 7/7/2008





Other reviews about Trastuzumab on wordpress

ALLTO Study Evaluates the Role of Lapatinib (Tykerb) in Adjuvant Therapy of Her-2 Positive Breast Cancer
  by bmirtsching
CORT has opened the NCCTG N063D (BIG 2-06) study for adjuvant therapy of her-2 positive breast cancer.  This study is a worldwide study funded by the National Cancer Institute […]


TDM1 (Trastuzumab-DM1) Immunoconjugate Drug Therapy Study Open at CORT
  by bmirtsching
A phase III study of Trastuzumab-DM1 for treatment of relapsed her-2 positive metastatic breast cancer is open at CORT.  Trastuzumab (Herceptin)  is a monoclonal antibody against the her-2 protein, […]


In Trastuzumab-Resistant Metastatic Breast Cancer, Small Molecule Inhibitor Shows Promise
  by healtherm2
Fox Chase Cancer Center researchers report that a combination of trastuzumab and neratinib (HKI-272) a novel small molecule inhibitor of the HER2 receptor (ErbB2) appears active in women […]


ImmunoGen, Inc. Announces Encouraging Trastuzumab-DM1 Phase II Clinical Findings Presented At ASCO
  by healtherm2
ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced the presentation of encouraging trastuzumab-DM1 (T-DM1) clinical data at the 2009 Annual Meeting of […]


Management and Prognosis: How Best to Treat Breast Cancer Patients
  by AACR Communications Staff
SAN ANTONIO - As therapies for breast cancer continue to emerge, the issues of how to best monitor success and gauge prognosis remain important questions. At the CTRC-AACR San […]


SABCS 2009 Interview with Kimberly L. Blackwell, M.D
  by AACR Communication Staff
The CTRC-AACR San Antonio Breast Cancer Symposium, Dec. 9-13, 2009, attracts world leaders in cancer research and treatment, including clinical oncologists, industry leaders, basic scientists and translational researchers […]


Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial
  by zedie
Purpose We investigated the incidence of cardiac adverse events in patients with early breast cancer in the Herceptin Adjuvant (HERA) trial who were treated with 1 year of […]


A New Treatment Option for patients with Gastric Cancer
  by wngai
Gastric cancer is the fourth most commonly diagnosed cancer and the second most common cause of cancer-related deaths worldwide.  Previous study has found that patients with operable […]


Troponin I Provides Insight Into Cardiotoxicity and the Anthracycline-Trastuzumab Interaction
  by zedie
Great strides have been made in the treatment of breast cancer during the last few decades, yet cardiotoxicity of anticancer […]


HER2-positive Breast Cancer with Brain Metastases? Use Lapitinibi (Tykerb) and Capecitibine (Xeloda) but NOT Trastuzumab (Herceptin)
  by wngai
Human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) is a disease that accounts for up to one third of all invasive breast tumors. The natural history […]



Other reviews about Trastuzumab on web:

Trastuzumab (INN; trade name Herceptin) is a monoclonal antibody that interferes with the HER2/neu receptor. The HER receptors are proteins that are embedded in the cell ... Trastuzumab - Wikipedia, the free encyclopedia


This page contains brief information about trastuzumab and a collection of links to more information about the use of this drug, related news and research results, and ongoing ... Trastuzumab - National Cancer Institute


Trastuzumab Key Terms: Antibody , Humanization , IgG , Interleukins . Definition Trastuzumab is a humanized monoclonal antibody produced by Trastuzumab: Information from Answers.com


Herceptin (trastuzumab) is part of a treatment plan for the adjuvant treatment of patients with HER2 overexpressing, node-positive HER2+ breast cancer. Who is Herceptin for? Herceptin® (trastuzumab) HER2+ Breast Cancer Treatment


Learn more about Trastuzumab. Find the Web's best health guides, medical reports, news, videos and tools for Trastuzumab. Share Trastuzumab experiences and get advice from experts. Trastuzumab Overview - References, Advice, News, Videos, Coping ...


All about Trastuzumab. View complete and up to date Trastuzumab information - part of the Drugs.com trusted medication database. Trastuzumab Facts and Comparisons at Drugs.com


Trastuzumab is a monoclonal antibody used in combination with chemotherapy for the treatment of HER2 overexpressing, node-positive breast cancer. Research information and side ... Trastuzumab Information: Description, Side Effects and Trastuzumab ...


About Your Treatment. Your doctor has ordered the drug trastuzumab to help treat your illness. The drug is given by injection into a vein.This medication is used to treat ... Trastuzumab - Kosmix : Reference, Videos, Images, News, Shopping ...


Information on many different cancers includes symptoms, cancer detection and prevention, and treatment options. trastuzumab - Cancer Information (Cancers, Symptoms, Treatment) on ...


Learn about the prescription medication Herceptin (Trastuzumab), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Herceptin (Trastuzumab) Drug Information: Uses, Side Effects, Drug ...





Featured Reviews

Reviews Perfluoroalkylpolyether

Skin Exposure Paste Drug Description SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS (SERPACWA) DRUG DESCRIPTION SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS (SERPACWA) is a viscous white paste containing a...
Read More  |  Review This
Reviews Acetylcysteine Injection

Acetadote Drug Description ACETADOTE (acetylcysteine) Injection DRUG DESCRIPTION Acetylcysteine injection is an intravenous (I.V.) medication for the treatment of acetaminophen overdose. Acetylcysteine is the nonproprietary name for...
Read More  |  Review This
Reviews Livalo

Livalo Drug Description LIVALO (pitavastatin) Tablet, Film Coated for Oral use DRUG DESCRIPTION LIVALO (pitavastatin) is an inhibitor of HMG-CoA reductase. It is a synthetic lipid-lowering agent for oral administration. The empirical...
Read More  |  Review This
Reviews Cancidas

Cancidas Drug Description CANCIDAS (caspofungin acetate) for Injection, for Intravenous use DRUG DESCRIPTION What are the possible side effects of caspofungin (Cancidas)? Get emergency medical help if you have any of these signs...
Read More  |  Review This
Reviews Humira

Humira Drug Description HUMIRA (adalimumab) Injection, Solution for Subcutaneous Use WARNINGS SERIOUS INFECTIONS Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....